Oricell Therapeutics Co., Ltd. announced completion of a US$110 million+ pre‑IPO financing round, positioning the cell therapy innovator for capital market entry and accelerated global clinical development. The round was co‑led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with participation from an international sovereign wealth fund, E‑Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.
Financing Overview
Component
Detail
Amount Raised
>US$110 million
Round
Pre‑IPO financing
Co‑Leads
Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, leading global healthcare fund
Participants
International sovereign wealth fund, E‑Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, Talon Capital
Use of Proceeds
Global expansion, clinical development, technology platform strengthening, capital market preparation
Lead Product: Ori‑C101
Attribute
Detail
Product
Ori‑C101
Modality
Autologous CAR‑T therapy
Target
GPC3 (glypican‑3)
Indication
Advanced hepatocellular carcinoma (HCC)
Status
IIT (investigator‑initiated trials) completed; pivotal trials on track
Differentiation
Potential to become first approved CAR‑T therapy for HCC worldwide
Clinical & Strategic Positioning
Unmet Need: HCC is the 6th most common cancer globally with ~900,000 annual new cases; 5‑year survival <20% for advanced disease; no approved CAR‑T therapies for solid tumors
Clinical Validation: Positive IIT data supports registrational trial initiation; potential BLA submission 2027‑2028 in China with US/EU pathways to follow
First‑Mover Advantage: GPC3‑targeted CAR‑T addresses >70% of HCC cases expressing target; category leadership in solid tumor cell therapy
Technology Platform & Pipeline
Platform Capability
Application
Secreted CAR‑T
Enhanced tumor penetration and persistence
Rapid‑manufacturing
Reduced vein‑to‑vein time improving patient access
In vivo CAR‑T
Eliminating ex vivo manufacturing complexity
Multi‑target, multi‑mechanism
Addressing tumor heterogeneity and resistance
Pipeline Depth: Continuous incubation of next‑generation CAR‑T products targeting diverse solid tumor indications beyond HCC
Market Context & Outlook
Solid Tumor CAR‑T Market:US$15‑20 billion addressable opportunity; current approved therapies limited to hematologic malignancies
HCC Therapeutic Landscape: Dominated by TKIs (sorafenib, lenvatinib) and IO combinations; CAR‑T offers potential curative mechanism for refractory patients
Revenue Potential: Peak Ori‑C101 sales projected at US$500 million‑1 billion globally by 2033, assuming first‑to‑market position and 15‑25% penetration in 3L+ HCC
IPO Trajectory: Pre‑IPO round structure suggests Hong Kong or US listing targeted 2026‑2027; valuation expected to exceed US$500 million at IPO
Platform Value: Full‑spectrum CAR‑T technology system supports multiple partnership opportunities and pipeline expansion into gastric, lung, and ovarian cancers
Forward‑Looking Statements This brief contains forward‑looking statements regarding clinical trial outcomes, regulatory pathways, financing deployment, and capital market timing for Oricell Therapeutics. Actual results may differ due to risks including solid tumor CAR‑T efficacy challenges, manufacturing scalability, competitive advances, and IPO market conditions.-Fineline Info & Tech
By Fineline Cube 